Share on

Global Capecitabine Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report - Segmented By Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer and Others), Drug Formulation (Tablets and Capsules) & Region - Industry Forecasts (2023 to 2028)

Published: March, 2023
ID: 6192
Pages: 175
Formats: report pdf report excel report power bi report ppt

Capecitabine Market Size (2023 to 2028)

The global capecitabine market is expected to record a CAGR of 6.2% throughout the forecast period.

Capecitabine is a chemotherapy drug that works by reducing or preventing the progression of cancer cells. This medication is to treat cancers such as colorectal cancer, breast cancer, and gastric cancer. According to the American Cancer Society report, in 2017, there were predictable 135,431 new cases and 50,260 deaths from colon and rectal cancer in the US.   


The increasing demand for target drugs to decrease possible side effects without affecting healthy cells is likely to accelerate the application of the global capecitabine market.

The growing encumbrance for patients detected with cancer and tumors is to stimulate the market. According to the World Health Organization report, cancer is one of the leading causes of death worldwide, and it is estimated that about 9.6 million deaths in 2018. Besides, Around 628,000 women have died from breast cancer, which accounts for about 15% of all cancer decreases in women worldwide. Also, a sharp increase in health spending continued R&D activities in cancer treatment should offer new market opportunities.

Additionally, rising awareness programs from administrations and private administrations such as Cancer Care, Cancer Research UK, and Cancer Suraksha Scheme drive growth in the Capecitabine market during the period. 


However, the high cost of Capecitabine and strict government regulations related to the safety and efficacy of Capecitabine is hampering the growth of the global capecitabine market. 




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Application, Drug Formulation, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa


This research report on the global capecitabine market has been segmented and sub-segmented into the following categories and analyzed market size and forecast for each segment until 2027.

Capecitabine Market – By Application:

  • Colon Cancer          
  • Rectal Cancer         
  • Breast Cancer        
  • Gastric Cancer       
  • Others      

Capecitabine Market – By Drug Formulation:

  • Tablets      
  • Capsules  

Capecitabine Market – By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American region accounted for the largest share of the Capecitabine market, followed by Europe and the Asia Pacific in 20202 Asia Pacific is to witness the highest CAGR in the coming years.


Some of the promising companies dominating the global capecitabine market profiled in this report are Novartis AG, Sensus Healthcare, RXi Pharmaceuticals, Inc., Sonoma Pharmaceuticals, Inc., Perrigo Company plc, Bristol-Myers Squibb Company, Pacific World Corporation, Valeant Pharmaceuticals International, Inc., Revitol Corporation and Avita Medical Limited.


  • In April 2019, Armas Pharmaceuticals, Inc. was delighted to publicize the launch of its second and third generic products, Imatinib and Capecitabine, for the US market. These products will be the first reliable oral oncology products for Weapons. Capecitabine will be available in 150mg, and 500mg doses and Imatinib will be available in 100mg and 400mg doses.
  • In July 2017, headquartered at Hikma Pharmaceuticals has launched 150mg and 500mg tablets of Capecitabine, the generic equivalent of Xeloda, through its affiliate West-Ward Pharmaceuticals. West-Ward Capecitabine tablets are indicated for adjuvant therapy in patients with colon cancer C, as monotherapy for metastatic colorectal cancer.
  • In August 2014, Mylan Inc. (Nasdaq: MYL) announced the release of Capecitabine Tablets USP, 150mg and 500mg, the generic version of Genentech Xeloda® tablets. Mylan received final approval from the United States Food and Drug Administration (FDA) for its Short Drug Application (ANDA) for this product. 

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample